tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Ainos advances Veldona oral interferon drug platform

Ainos (AIMD) announced progress in advancing its oral interferon drug platform, Veldona in the rare disease space. The Taiwan FDA has approved the company’s clinical trial for human immunodeficiency virus-related oral warts, while Institutional Review Board clearance has been granted for its upcoming Sjogren’s Syndrome study. The upcoming Taiwan trials will be conducted using the company’s next-generation Veldona formulation.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1